FDA Brief

Warning letters Drugs

FDA warning letter to

RC Outsourcing, LLC

High riskIssued Mar 20Posted Apr 21Center for Drug Evaluation and Research (CDER)

FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

What happened

FDA inspected the facility from August 18 to August 28, 2025 and issued a Form FDA 483 (the list of problems found at the end of an inspection) on August 28, 2025. Investigators found sterile drugs and container parts exposed to air below ISO 5 quality, weak environmental monitoring, incomplete investigations, and missing identity testing of ingredients, and the firm recalled four lots of Bevacizumab on September 22, 2025 because it could not assure they were sterile. FDA reviewed the firm's responses of September 19, October 28, and November 21, 2025, and later correspondence of December 31, 2025, and found several corrective actions incomplete or undocumented.

What FDA found

  1. Sterile drugs and dropper bottle caps were handled in air dirtier than the required ISO 5 grade, so the products could become contaminated.

    Section 501(a)(2)(A) of the FD&C Act (insanitary conditions)
  2. The firm did not properly monitor the air and surfaces in the area where sterile drugs are made.

    21 CFR 42(c)(10)(iv), as cited in the letter
  3. The firm lacked written procedures, including validation of its sterile process, to prevent microbe contamination of products meant to be sterile.

    21 CFR 211.113(b)
  4. The firm did not fully investigate a bevacizumab sterility failure or the repeated microbe findings on operators' gown sleeves.

    21 CFR 211.192
  5. The firm did not test each shipment of each ingredient lot for identity or check the reliability of its suppliers' test results.

    21 CFR 211.84(d)(1), 211.84(d)(2)
  6. The firm repackaged povidone-iodine and made bevacizumab without FDA-approved applications, and the bevacizumab label states 1.25 mg when the syringe actually contains 1.75 mg.

    Section 505(a) and section 502(a) of the FD&C Act

What FDA wants

FDA asks the firm to write back within 15 working days describing each corrective step, how recurrence will be prevented, and supporting documentation. FDA also strongly recommends a full outside review of operations, especially aseptic processing, by a consultant with sterile drug manufacturing expertise.

Who should pay attention

  • hospitals and clinics that buy compounded sterile drugs from outsourcing facilities
  • outsourcing facilities and compounding pharmacies making sterile products
  • firms that rely on contract test labs or supplier certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk